Relative efficacy of antianginal drugs used as add-on therapy in patients with stable angina: A systematic review and meta-analysis.
Jan 12, 2015
Overview:Background and knowledge gap Stable angina is a form of coronary artery disease. Its potential to progress requires the most appropriate treatment in order to reduce the incapacitating effect of an acute angina attack and to avoid long-term cardiovascular events.... more
Nicorandil and Long-Acting Nitrates: Vasodilator Therapies for the Management of Chronic Stable Angina Pectoris
Jan 14, 2020
Overview: Stable angina pectoris is the most prevalent clinical manifestation of coronary heart disease. While the overall prognosis in patients with stable angina is good, with a low yearly event rate of ~1–2 %,1 for many, adequate symptom control can... more
Role Of Anti-Inflammatory Interventions In Coronary Artery Disease: Understanding CANTOS
Mar 02, 2020
Overview: Coronary artery disease (CAD) is the leading cause of death in most countries. Compelling evidence from epidemiological, genetic and clinical studies as well as experiments in animal models has unquestionably established that elevated concentrations of cholesterol (mainly transported by... more
Viewpoint: Recent Advances In Intracoronary Imaging For Vasa Vasorum Visualisation
Feb 08, 2019
Overview: Vasa Vasorum The coronary arterial wall generally consists of the tunica intima, tunica media and tunica adventitia. In particular, the coronary adventitia harbours the vasa vasorum (VV),which has a diameter of 50–300 μm and plays an important role as... more
Management Of Severe Dyslipidaemia: Role Of PCSK9 Inhibitors
Dec 12, 2019
Overview: Therapeutic targeting of dyslipidaemia has been one of the major successes in cardiovascular medicine over the last three decades. On the basis of unequivocal evidence from animal models through to both population and genetic studies in humans, there is... more
Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease
Findings From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial
Mar 21, 2016
Overview:Valvular heart disease (VHD) is associated with a higher incidence of thromboembolic events, regardless of the underlying cardiac rhythm [1]. Atrial fibrillation (AF) is associated with a higher incidence of thromboembolic events in patients with rheumatic mitral stenosis or in... more
Cardiovascular Risk Management Targeting Inflammation In Addition To Lipid-Lowering Therapy
Dec 13, 2017
Overview:Myocardial infarction is often caused by the rupture of unstable plaque in atherosclerosis with mild-to-moderate stenosis. Research has revealed that local tissue inflammation is closely involved in the rupture of atherosclerotic plaque.1 Stabilization of atherosclerotic plaque by strictly managing the... more
New Advances in the Management of Refractory Angina Pectoris
Apr 10, 2020
Overview: Refractory angina (RA) is defined as chronic angina-type chest pain (duration ≥ 3 months) associated with reversible ischaemia that persists despite optimal medical, interventional and surgical management.1 The clinical burden of RA is growing due to an ageing population... more
Myocardial infarction with non-obstructive coronary arteries (MINOCA)
Jul 25, 2017
Overview:By Professor Stefan Agewall A sizeable proportion of MIs, ranging between 1% and 14%, occur in the absence of obstructive coronary artery disease. The diagnostic criteria of MINOCA fulfill the universal criteria of myocardial infarction, but without coronary artery stenosis... more
Anticoagulation in CVD: Clinical Implications of the COMPASS Study
Jun 17, 2020
Overview: Anticoagulation In Patients With Ischaemic Heart Disease And Peripheral Arterial Disease: Clinical Implications Of COMPASS Study Atherosclerotic cardiovascular disease (CVD) comprises a large number of related pathologies, including ischaemic heart disease and peripheral arterial disease (PAD).1 This group of... more